Breeze3:Study of Gabapentin Extended Release in the Treatment of Vasomotor Symptoms(Hot Flashes)in Postmenopausal Women

Inclusion Criteria: * Generally healthy, postmenopausal women who seek treatment for hot flashes * Patients using hormone replacement therapy(HRT) must be willing to discontinue treatment * Patients must be experiencing moderate to severe hot flashes * Patients must be able to sign the informed consent * Patients must be able to enter simple commands and complete questionnaires on the frequency and severity of their hot flashes using an electronic diary Other inclusions apply. Exclusion Criteria: * Patients with hypersensitivity to Gabapentin * Patients with severe chronic diarrhea, chronic constipation, uncontrolled irritable bowel syndrome (IBS) or unexplained weight loss * Patients treated with estrogen pellets or injectable progestin drug therapy within 6 months. * Patients currently treated with Gabapentin or Pregabalin for any indication, including vasomotor symptoms Other exclusions apply.